1
|
Advances in Infectious Disease Vaccine Adjuvants. Vaccines (Basel) 2022; 10:vaccines10071120. [PMID: 35891284 PMCID: PMC9316175 DOI: 10.3390/vaccines10071120] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/01/2022] [Accepted: 07/04/2022] [Indexed: 02/01/2023] Open
Abstract
Vaccines are one of the most significant medical interventions in the fight against infectious diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the worldwide transmission to eradication levels of infectious diseases, including smallpox, diphtheria, hepatitis, malaria, and influenza. However, the complexity of developing safe and effective vaccines remains a barrier for combating many more infectious diseases. Immune stimulants (or adjuvants) are an indispensable factor in vaccine development, especially for inactivated and subunit-based vaccines due to their decreased immunogenicity compared to whole pathogen vaccines. Adjuvants are widely diverse in structure; however, their overall function in vaccine constructs is the same: to enhance and/or prolong an immunological response. The potential for adverse effects as a result of adjuvant use, though, must be acknowledged and carefully managed. Understanding the specific mechanisms of adjuvant efficacy and safety is a key prerequisite for adjuvant use in vaccination. Therefore, rigorous pre-clinical and clinical research into adjuvant development is essential. Overall, the incorporation of adjuvants allows for greater opportunities in advancing vaccine development and the importance of immune stimulants drives the emergence of novel and more effective adjuvants. This article highlights recent advances in vaccine adjuvant development and provides detailed data from pre-clinical and clinical studies specific to infectious diseases. Future perspectives into vaccine adjuvant development are also highlighted.
Collapse
|
2
|
Akelew Y, Andualem H, Ebrahim E, Atnaf A, Hailemichael W. Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy. Immun Inflamm Dis 2022; 10:e573. [PMID: 34861106 PMCID: PMC8926508 DOI: 10.1002/iid3.573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/07/2021] [Accepted: 11/24/2021] [Indexed: 12/19/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), an emerging virus in late 2019 causing coronavirus disease 2019 (COVID‐19), has caused a catastrophic effect, resulting in an unprecedented global crisis. The immunopathology of COVID‐19 appears to be clearly associated with a dysregulated immune response leading to organ failure and death. Similarly, over two billion people worldwide are infected with helminth, with those living in low‐middle‐income countries disproportionately affected. Helminth infections have been shown to possess immunomodulatory effects in several conditions. Helminth co‐infection in COVID‐19 patients is one of the potential reasons for global attention to answer why COVID‐19 severity is still lower in helminth endemic countries. Recent studies have shown that helminth endemic countries showed fewer cases and deaths so far and helminth co‐infection might reduce the severity of COVID‐19. Moreover, lessons from other diseases with helminth co‐infection have been shown to substantially reduce vaccine efficacy that could also be implicated for COVID‐19. This immunomodulatory effect of helminth has intended and unintended consequences, both advantageous and disadvantageous which could decrease the severity of COVID‐19 and COVID‐19 vaccine efficacy respectively. Herewith, we discuss the overview of COVID‐19 immune response, immunomodulatory effects of helminth co‐infections in COVID‐19, lessons from other diseases, and perspectives on the efficacy of COVID‐19 vaccines.
Collapse
Affiliation(s)
- Yibeltal Akelew
- Immunology and Molecular Biology, Medical Laboratory Sciences, College of Health Sciences Debre Markos University Debre Markos Ethiopia
| | - Henok Andualem
- Immunology and Molecular Biology, Medical Laboratory Sciences, College of Health Sciences Debre Tabor University Debre Tabor Ethiopia
| | - Endris Ebrahim
- Immunology and Molecular Biology, Medical Laboratory Sciences, College of Health Sciences Wollo University Dessie Ethiopia
| | - Aytenew Atnaf
- Hematology and Immunohematology, Medical Laboratory Sciences, College of Health Sciences Debre Markos University Debre Markos Ethiopia
| | - Wasihun Hailemichael
- Immunology and Molecular Biology, Medical Laboratory Sciences, College of Health Sciences Debre Tabor University Debre Tabor Ethiopia
| |
Collapse
|
3
|
Greco M, Cucci F, Portulano P, Lazzari RA, Caldararo C, Sicuro F, Catanese C, Lobreglio G. Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers. J Clin Med Res 2022; 13:549-555. [PMID: 35059073 PMCID: PMC8734511 DOI: 10.14740/jocmr4590] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 09/29/2021] [Indexed: 12/19/2022] Open
Abstract
Background Vaccine-induced immunity is at present the main strategy to stop the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent evidences suggested a protective effect of influenza vaccination against coronavirus disease 2019 (COVID-19) severity, while impact on the immune response to BNT162b2 messenger RNA (mRNA) vaccine is under investigation. Methods We aimed to evaluate this aspect in a cohort of 297 healthcare workers (108 males, 189 females) after seasonal influenza vaccination compared to no-flu-vaccination. VAX+ (165 individuals; 63 males and 102 females) had tetravalent influenza vaccine, and VAX- (132 individuals; 45 males and 87 females) had no flu vaccination. Anti-spike-receptor binding domain (RBD) level was tested 15 - 70 days after BNT162b2 second inoculum. Results Increased antibody response was observed in total VAX+ compared to VAX- (2,047.4 vs. 1,494.2 binding antibody unit (BAU)/mL, P = 0.0039), independently from gender and body mass index (BMI). Younger total individuals (< 35 years) showed significant increase of the level of binding antibodies (2,184.8 vs. 1,590.9 BAU/mL, P = 0.0038) compared to ≥ 35 years; young/old difference was lost restricting to VAX+ subgroup. Flu vaccinations appear associated to better antibody response in older individuals (P = 0.027, ≥ 35 years VAX+ vs. VAX-). A decreasing trend during time was observed for both VAX+ and VAX-, except for < 35 years VAX- individuals. Early response was higher in VAX+ compared to VAX-; however a more rapid waning was observed in VAX+ subjects. Conclusions Our data showed better antibody response to SARS-CoV-2 vaccine in subjects already vaccinated against seasonal influenza; this may represent one of the mechanisms underlying the cross-protective effects of influenza vaccination against heterologous infections reported in recent epidemiological studies.
Collapse
Affiliation(s)
- Marilena Greco
- Clinical Pathology and Microbiology, Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| | - Federico Cucci
- Nursing Science University of Bari at Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| | | | | | - Cosimo Caldararo
- Nursing Science University of Bari at Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| | - Fernando Sicuro
- Clinical Pathology and Microbiology, Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| | - Carmelo Catanese
- Intensive Care Unit, Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| | - Giambattista Lobreglio
- Clinical Pathology and Microbiology, Vito Fazzi General Hospital ASL-Lecce, Lecce, Italy
| |
Collapse
|
5
|
Puro V, Castilletti C, Agrati C, Goletti D, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R, Colavita F, Meschi S, Matusali G, Lapa D, Najafi Fard S, Aiello A, Farrone C, Gallì P, Capobianchi MR, Ippolito G. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines (Basel) 2021; 9:vaccines9060615. [PMID: 34201065 PMCID: PMC8229609 DOI: 10.3390/vaccines9060615] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/01/2021] [Accepted: 06/04/2021] [Indexed: 01/14/2023] Open
Abstract
Vaccination against SARS-CoV-2 is considered the most effective method of prevention to contain the pandemic. While highly effective SARS-CoV-2 vaccines are being applied on a large-scale, whether and to what extent the strength of the vaccine-induced immune response could be further potentiated is still an object of debate. Several reports studied the effect of different vaccines on the susceptibility and mortality of COVID-19, with conflicting results. We aimed to evaluate whether previous influenza and/or pneumococcal vaccination had an impact on the specific immune response to the SARS-CoV-2 BNT162b2 mRNA vaccine. The study population consists of 710 workers from our Institute who completed the BNT162b2 schedule and have been tested at least once after the second dose, from 27 December 2020 up to 15 April 2021. Of these, 152 (21.4%) had received an influenza and 215 (30.3%) a concomitant influenza and pneumococcal vaccination, a median of 102 days before the second dose of BNT162b2. Overall, 100% of workers were tested for anti-Spike receptor-binding domain (anti-S/RBD) antibodies, 224 workers for neutralization titer (Micro-neutralization assay, MNA), and 155 workers for a spike-specific T cell interferon-γ response (IFN-γ). The levels of anti-S/RBD, MNA and IFN-γ were evaluated and compared according to sex, age, involvement in direct care of COVID-19 patients, and previous influenza/pneumococcal vaccination. At the univariate analysis, no statistically significant association was observed with regard to a previous influenza and pneumococcal vaccination. A significant lower anti-S/RBD response was observed according to an older age and male sex, while MNA titers were significantly associated to sex but not to age. At the multivariable analysis, workers receiving a concomitant influenza and pneumococcal vaccination or only influenza showed a 58% (p 0.01) and 42% (p 0.07) increase in MNA titers, respectively, compared to those who did not receive an influenza/pneumococcal vaccination. Female workers showed an 81% MNA and a 44% anti-S/RBD increase compared to male workers (p < 0.001). Compared to workers aged 21 to 49 years, those aged 50 or older were associated with a reduction in the anti-S/RBD (16%; p 0.005), MNA (31%; p 0.019), and IFN.g (32%) immune response. Maintaining the influenza and pneumococcal immunization program for the coming season, in which COVID-19 could still be spreading, remains strongly recommended to protect those who are more vulnerable and to limit the potential burden of these infections on the healthcare system.
Collapse
|
6
|
Zumla A, Chakaya J, Khan M, Fatima R, Wejse C, Al-Abri S, Fox GJ, Nachega J, Kapata N, Knipper M, Orcutt M, Goscé L, Abubakar I, Nagu TJ, Mugusi F, Gordon AK, Shanmugam S, Bachmann NL, Lam C, Sintchenko V, Rudolf F, Amanullah F, Kock R, Haider N, Lipman M, King M, Maeurer M, Goletti D, Petrone L, Yaqoob A, Tiberi S, Ditiu L, Sahu S, Marais B, Issayeva AM, Petersen E. World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. Int J Infect Dis 2021; 113 Suppl 1:S1-S6. [PMID: 33746094 DOI: 10.1016/j.ijid.2021.03.046] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- Alimuddin Zumla
- Department of Infection, Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
| | - Jeremiah Chakaya
- Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
| | - Mishal Khan
- Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
| | - Razia Fatima
- National TB Control Program, Islamabad, Common Unit (HIV, TB, Malaria), Chak Shahzad, Islamabad, Pakistan.
| | - Christian Wejse
- Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark.
| | - Seif Al-Abri
- Directorate General for Disease Surveillance and Control, Ministry of Health, Oman.
| | - Greg J Fox
- WHO Collaborating Centre for Tuberculosis, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
| | - Jean Nachega
- Department of Medicine and Center for Infectious Diseases, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa; University of Pittsburgh, Pittsburgh, PA, USA; University of Stellenbosch, South Africa.
| | - Nathan Kapata
- Ministry of Health, Zambia National Public Health Institute, Lusaka, Zambia.
| | - Michael Knipper
- Institute for the History of Medicine, University Justus Liebig Giessen, Germany.
| | - Miriam Orcutt
- Institute for Global Health, University College London, United Kingdom.
| | - Lara Goscé
- University College London, United Kingdom.
| | - Ibrahim Abubakar
- Institute for Global Health, University College London, United Kingdom.
| | - Tumaini Joseph Nagu
- Muhimbili University of Health and Allied Sciences Dar es Salaam, Dar es Salaam, Tanzania.
| | - Ferdinand Mugusi
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
| | - Alice Kizny Gordon
- Centre for Infectious Diseases and Microbiology (CIDM), Institute of Clinical Pathology and Medical Research (ICPMR), The University of Sydney, New South Wales, Australia.
| | - Sivakumar Shanmugam
- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
| | - Nathan Lloyd Bachmann
- Centre for Infectious Diseases and Microbiology (CIDM), University of Sydney, New South Wales, Australia.
| | - Connie Lam
- Institute of Clinical Pathology and Medical Research (ICPMR), Westmead, New South Wales, Australia.
| | - Vitali Sintchenko
- WHO Collaborating Centre for Tuberculosis, Marie Bashir Institute for Infectious Diseases and Biosecurity and Centre for Infectious Diseases and Microbiology (CIDM), University of Sydney, New South Wales, Australia.
| | - Frauke Rudolf
- Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark; Bandim Health Project, INDEPTH Network, Apartado 861, Bissau, Guinea-Bissau.
| | | | - Richard Kock
- Royal Veterinary College, Hatfield, United Kingdom.
| | - Najmul Haider
- Pathobiology and Population Sciences, The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom.
| | - Marc Lipman
- Respiratory Medicine, Royal Free London NHS Foundation Trust, UCL Respiratory Medicine, University College London, London, United Kingdom.
| | - Michael King
- NTM Patient Care UK, The Grove Centre London, United Kingdom.
| | - Markus Maeurer
- Champalimaud Centre for the Unknown, Lisbon, Portugal; University of Mainz, Mainz, Germany.
| | - Delia Goletti
- Translational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"- IRCCS, Rome, Italy.
| | - Linda Petrone
- Translational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"- IRCCS, Rome, Italy.
| | - Aashifa Yaqoob
- Common Management Unit (TB, HIV & Malaria), Islamabad, Pakistan.
| | - Simon Tiberi
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
| | | | | | - Ben Marais
- WHO Collaborating Centre for Tuberculosis and the Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, New South Wales, Australia.
| | | | - Eskild Petersen
- Institute for Clinical Medicine, Faculty of Health Science, University of Aarhus, Denmark; European Society for Clinical Microbiology and Infectious Diseases, ESCMID, Basel, Switzerland; International Society for Infectious Diseases, ISID, Boston, USA.
| |
Collapse
|